[en] Depositions of proteins in form of amyloid and non-amyloid plaques are common pathogenic signs of more than 20 degenerative diseases affecting the central nervous system or a variety of peripheral tissues. Among the neuropathological conditions, Alzheimer's, Parkinson's and the prion diseases, such as Creutzfeldt-Jakob disease (CJD), present ambiguities as regarding their differential diagnosis. At present, their diagnosis must be confirmed by post-mortem examination of the brain. Currently the ante-mortem diagnosis is still based on the integration of multiple data (clinical, paraclinical and biological analyses) because no unique marker exists for such diseases. The detection of specific biomarkers would be useful to develop a differential diagnostic, distinguishing not only different neurodegenerative diseases but also the disease from the non-pathological effects of aging. Several neurodegenerative biomarkers are present at very low levels during the early stages of the disease development and their ultra-low detection is needed for early diagnosis, which should permit more effective therapeutic interventions, before the disease concerned can progress to a stage where considerable damage to the brain has already occurred. In the case of prion diseases, there are concerns regarding not only patient care, but the wider community too, with regard to the risk of transmission of prions, especially during blood transfusion, for which, four cases of variant CJD infection associated with transfusion of non-leukocyte-depleted blood components have been confirmed. Therefore the development of techniques with high sensitivity and specificity represent the major challenge in the field of the protein misfolding diseases. In this paper we review the current analytical and/or biochemical diagnostic technologies used mainly in prion, but also in Alzheimer and Parkinson diseases and emphasizing work on the protein detection as a surrogates and specific biomarker in the body fluid of patients (urine, CSF and blood). This review highlights the urgency of the development of early and sensitive diagnostics in terms of therapeutic challenge.
Dupiereux-Fettweis, Ingrid ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie humaine
Zorzi, Willy ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie humaine - Département des sciences biomédicales et précliniques
Quadrio, Isabelle
Perret-Liaudet, Armand
Kovacs, Gabor G
Heinen, Ernst ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie humaine
Elmoualij, Benaïssa ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie humaine
Language :
English
Title :
Creutzfeldt-jakob, Parkinson, lewy body dementia and Alzheimer diseases: from diagnosis to therapy.
Publication date :
2009
Journal title :
Central Nervous System Agents in Medicinal Chemistry
Prusiner, S. B. Shattuck lecture--neurodegenerative diseases and prions. N. Engl. J. Med., 2001, 344 (20), 1516-1526.
Beyer, K.; Ariza, A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J. Neuropathol. Exp. Neurol., 2007, 66 (11), 965-974.
Wisniewski, T.; Aucouturier, P.; Soto, C.; Frangione, B. The prionoses and other conformational disorders. Amyloid, 1998, 5 (3), 212-224.
Dubois, B.; Feldman, H. H.; Jacova, C.; Dekosky, S. T.; Barberger-Gateau, P.; Cummings, J.; Delacourte, A.; Galasko, D.; Gauthier, S.; Jicha, G.; Meguro, K.; O'brien, J.; Pasquier, F.; Robert, P.; Ros- sor, M.; Salloway, S.; Stern, Y.; Visser, P. J.; Scheltens, P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol., 2007, 6 (8), 734-746.
Lumley, J. S. Serious Hazards of Transfusion Committee. The impact of Creutzfeldt Jakob disease on surgical practice. Ann. R. Coll. Surg. Engl., 2008, 90 (2), 91-94.
Zou, S.; Fang, C. T.; Schonberger, L. B. Transfusion transmission of human prion diseases. Transfus. Med. Rev., 2008, 22 (1), 58-69.
Ironside, J. W.; Head, M. W. Variant Creutzfeldt-Jakob disease and its transmission by blood. J. Thromb. Haemost., 2003, 1 (7), 1479-1486.
Musial, A.; Bajda, M.; Malawska, B. Recent developments in cho- linesterases inhibitors for Alzheimer's disease treatment. Curr. Med. Chem., 2007, 14 (25), 2654-2679.
Stewart, L. A.; Rydzewska, L. H.; Keogh, G. F.; Knight, R. S. Systematic review of therapeutic interventions in human prion disease. Neurology, 2008, 70 (15), 1272-1281.
Prusiner, S. B. Prions. Proc. Natl. Acad. Sci. USA, 1998, 95 (23), 13363-13383.
Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science, 1982, 216 (4542), 136-144.
Weissmann, C. Molecular genetics of transmissible spongiform encephalopathies. J. Biol. Chem., 1999, 274 (1), 3-6.
Liautard, J. P. [Prion diseases. The "prion" a remarkable infectious agents]. J. Soc. Biol., 1999, 193 (3), 311-316.
Caughey, B. Prion protein interconversions. Philos. Trans. R. Soc. Lond. B Biol. Sci., 2001, 356 (1406), 197-200.
Hill, A. F.; Desbruslais, M.; Joiner, S.; Sidle, K. C.; Gowland, I.; Collinge, J.; Doey, L. J.; Lantos, P. The same prion strain causes vCJD and BSE. Nature, 1997, 389 (6650), 448-50, 526.
Harris, D. A. Prion diseases. Nutrition, 2000, 16 (7-8), 554-556.
Belay, E. D. Transmissible spongiform encephalopathies in humans. Annu. Rev. Microbiol., 1999, 53, 283-314.
Brown, P.; Preece, M.; Brandel, J. P.; Sato, T.; McShane, L.; Zerr, I.; Fletcher, A.; Will, R. G.; Pocchiari, M.; Cashman, N. R.; d'Aignaux, J. H.; Cervenakova, L.; Fradkin, J.; Schonberger, L. B.; Collins, S. J. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology, 2000, 55 (8), 1075-1081.
Lane, K. L.; Brown, P.; Howell, D. N.; Crain, B. J.; Hulette, C. M.; Burger, P. C.; DeArmond, S. J. Creutzfeldt-Jakob disease in a pregnant woman with an implanted dura mater graft. Neurosurgery, 1994, 34 (4), 737-739.
Rappaport, E. B. Iatrogenic Creutzfeldt-Jakob disease. Neurology, 1987, 37 (9), 1520-1522.
Heath, C. A.; Barker, R. A.; Esmonde, T. F.; Harvey, P.; Roberts, R.; Trend, P.; Head, M. W.; Smith, C.; Bell, J. E.; Ironside, J. W.; Will, R. G.; Knight, R. S. Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. J. Neurol. Neurosurg. Psychiatry, 2006, 77 (7), 880-882.
Noguchi-Shinohara, M.; Hamaguchi, T.; Kitamoto, T.; Sato, T.; Nakamura, Y.; Mizusawa, H.; Yamada, M. Clinical features and diagnosis of dura mater graft associated Creutzfeldt Jakob disease. Neurology, 2007, 69 (4), 360-367.
Brown, P.; Brandel, J. P.; Preece, M.; Sato, T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology, 2006, 67 (3), 389-393.
Parchi, P.; Giese, A.; Capellari, S.; Brown, P.; Schulz-Schaeffer, W.; Windl, O.; Zerr, I.; Budka, H.; Kopp, N.; Piccardo, P.; Poser, S.; Rojiani, A.; Streichemberger, N.; Julien, J.; Vital, C.; Ghetti, B.; Gambetti, P.; Kretzschmar, H. Classification of sporadic Creutzfeldt Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol., 1999, 46 (2), 224-233.
Muller, W. E.; Laplanche, J. L.; Ushijima, H.; Schroder, H. C. Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech. Ageing Dev., 2000, 116 (2-3), 193-218.
Collins, S. J.; Sanchez-Juan, P.; Masters, C. L.; Klug, G. M.; van, Duijn C.; Poleggi, A.; Pocchiari, M.; Almonti, S.; Cuadrado-Corrales, N.; de Pedro-Cuesta, J.; Budka, H.; Gelpi, E.; Glatzel, M.; Tolnay, M.; Hewer, E.; Zerr, I.; Heinemann, U.; Kretszchmar, H. A.; Jansen, G. H.; Olsen, E.; Mitrova, E.; Alperovitch, A.; Brandel, J. P.; Mackenzie, J.; Murray, K.; Will, R. G. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain, 2006, 129 (Pt 9), 2278-2287.
Sanchez-Juan, P.; Green, A.; Ladogana, A.; Cuadrado-Corrales, N.; Saanchez-Valle, R.; Mitrovaa, E.; Stoeck, K.; Sklaviadis, T.; Kulczycki, J.; Hess, K.; Bodemer, M.; Slivarichova, D.; Saiz, A.; Calero, M.; Ingrosso, L.; Knight, R.; Janssens, A. C.; van Duijn, C. M.; Zerr, I. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology, 2006, 67 (4), 637-643.
Macfarlane, R. G.; Wroe, S. J.; Collinge, J.; Yousry, T. A.; Jager, H. R. Neuroimaging findings in human prion disease. J. Neurol. Neurosurg. Psychiatry, 2007, 78 (7), 664-670.
King, D. J.; Safar, J. G.; Legname, G.; Prusiner, S. B. Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites. J. Mol. Biol., 2007, 369 (4), 1001-1014.
Sayer, N. M.; Cubin, M.; Rhie, A.; Bullock, M.; Tahiri-Alaoui, A.; James, W. Structural determinants of conformationally selective, prion-binding aptamers. J. Biol. Chem., 2004, 279 (13), 13102-13109.
Bieschke, J.; Giese, A.; Schulz-Schaeffer, W.; Zerr, I.; Poser, S.; Eigen, M.; Kretzschmar, H. Ultrasensitive detection of pathological prion protein aggregates by dual color scanning for intensely fluorescent targets. Proc. Natl. Acad. Sci. USA, 2000, 97 (10), 5468-5473.
Safar, J.; Cohen, F. E.; Prusiner, S. B. Quantitative traits of prion strains are enciphered in the conformation of the prion protein. Arch. Virol. Suppl, 2000, 16, 227-235.
Saborio, G. P.; Permanne, B.; Soto, C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature, 2001, 411 (6839), 810-813.
Cervenakova, L.; Brown, P. Advances in screening test development for transmissible spongiform encephalopathies. Expert. Rev. Anti. Infect. Ther., 2004, 2 (6), 873-880.
Gofflot, S.; El, M. B.; Zorzi, D.; Melen, L.; Roels, S.; Quatpers, D.; Grassi, J.; Vanopdenbosch, E.; Heinen, E.; Zorzi, W. Immuno-quantitative polymerase chain reaction for detection and quantitation of prion protein. J. Immunoassay Immunochem., 2004, 25 (3), 241-258.
Zorzi, W.; El Moualij, B.; Zorzi, D.; Heinen, E.; Melen L. Detection method by PCR. (EP1232283), 2001.
Gofflot, S.; Deprez, M.; el, Moualij B.; Osman, A.; Thonnart, J. F.; Hougrand, O.; Heinen, E.; Zorzi, W. Immunoquantitative PCR for prion protein detection in sporadic Creutzfeldt-Jakob disease. Clin. Chem., 2005, 51 (9), 1605-1611.
Ferri, C. P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P. R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366 (9503), 2112-2117.
Wimo, A.; Jonsson, L.; Winblad, B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement. Geriatr. Cogn. Disord., 2006, 21 (3), 175-181.
Khachaturian, Z. S. Diagnosis of Alzheimer's disease. Arch. Neurol., 1985, 42 (11), 1097-1105.
Wong, C. W.; Quaranta, V.; Glenner, G. G. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc. Natl. Acad. Sci. USA, 1985, 82 (24), 8729-8732.
Grundke-Iqbal, I.; Iqbal, K.; Tung, Y. C.; Quinlan, M.; Wisniewski, H. M.; Binder, L. I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA, 1986, 83 (13), 4913-4917.
Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol., 1991, 82 (4), 239-259.
Thal, D. R.; Rub, U.; Orantes, M.; Braak, H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology, 2002, 58 (12), 1791-1800.
Schonheit, B.; Zarski, R.; Ohm, T. G. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol. Aging, 2004, 25 (6), 697-711.
Cotman, C. W.; Poon, W. W.; Rissman, R. A.; Blurton-Jones, M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J. Neuropathol. Exp. Neurol., 2005, 64 (2), 104-112.
McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 1984, 34 (7), 939-944.
Petersen, R. C.; Smith, G. E.; Waring, S. C.; Ivnik, R. J.; Tangalos, E. G.; Kokmen, E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol., 1999, 56 (3), 303-308.
Fischer, P.; Jungwirth, S.; Zehetmayer, S.; Weissgram, S.; Hoenigschnabl, S.; Gelpi, E.; Krampla, W.; Tragl, K. H. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology, 2007, 68 (4), 288-291.
Tapiola, T.; Pennanen, C.; Tapiola, M.; Tervo, S.; Kivipelto, M.; Hanninen, T.; Pihlajamaki, M.; Laakso, M. P.; Hallikainen, M.; Hamalainen, A.; Vanhanen, M.; Helkala, E. L.; Vanninen, R.; Nissinen, A.; Rossi, R.; Frisoni, G. B.; Soininen, H. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiol. Aging, 2008, 29 (1), 31-38.
Xu, G.; Antuono, P. G.; Jones, J.; Xu, Y.; Wu, G.; Ward, D.; Li, S. J. Perfusion fMRI detects deficits in regional CBF during memory- encoding tasks in MCI subjects. Neurology, 2007, 69 (17), 1650-1656.
Blennow, K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx., 2004, 1 (2), 213-225.
Hansson, O.; Zetterberg, H.; Buchhave, P.; Londos, E.; Blennow, K.; Minthon, L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol., 2006, 5 (3), 228-234.
Wiltfang, J.; Lewczuk, P.; Riederer, P.; Grunblatt, E.; Hock, C.; Scheltens, P.; Hampel, H.; Vanderstichele, H.; Iqbal, K.; Galasko, D.; Lannfelt, L.; Otto, M.; Esselmann, H.; Henkel, A. W.; Kornhuber, J.; Blennow, K. Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J. Biol. Psychiatry, 2005, 6 (2), 69-84.
Bouwman, F. H.; van der Flier, W. M.; Schoonenboom, N. S.; Van Elk, E. J.; Kok, A.; Rijmen, F.; Blankenstein, M. A.; Scheltens, P. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology, 2007, 69 (10), 1006-1011.
Tapiola, T.; Pirttila, T.; Mehta, P. D.; Alafuzofff, I.; Lehtovirta, M.; Soininen, H. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol. Aging, 2000, 21 (5), 735-740.
van Gool, W. A.; Kuiper, M. A.; Walstra, G. J.; Wolters, E. C.; Bolhuis, P. A. Concentrations of amyloid beta protein in cerebro-spinal fluid of patients with Alzheimer's disease. Ann. Neurol., 1995, 37 (2), 277-279.
Goedert, M.; Spillantini, M. G.; Potier, M. C.; Ulrich, J.; Crowther, R. A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J., 1989, 8 (2), 393-399.
Iqbal, K.; Alonso, Adel C.; El-Akkad, E.; Gong, C. X.; Haque, N.; Khatoon, S.; Tsujio, I.; Grundke-Iqbal, I. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration. J. Neural Transm. Suppl., 2002, (62), 309-319.
Vandermeeren, M.; Mercken, M.; Vanmechelen, E.; Six, J.; van, de, V; Martin, J. J.; Cras, P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem., 1993, 61 (5), 1828-1834.
Blennow, K.; Wallin, A.; Agren, H.; Spenger, C.; Siegfried, J.; Vanmechelen, E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol., 1995, 26 (3), 231-245.
Mori, H.; Hosoda, K.; Matsubara, E.; Nakamoto, T.; Furiya, Y.; Endoh, R.; Usami, M.; Shoji, M.; Maruyama, S.; Hirai, S. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett., 1995, 186 (2-3), 181-183.
Vigo-Pelfrey, C.; Seubert, P.; Barbour, R.; Blomquist, C.; Lee, M.; Lee, D.; Coria, F.; Chang, L.; Miller, B.; Lieberburg, I. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology, 1995, 45 (4), 788-793.
Andreasen, N.; Minthon, L.; Davidsson, P.; Vanmechelen, E.; Vanderstichele, H.; Winblad, B.; Blennow, K. Evaluation of CSF- tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol., 2001, 58 (3), 373-379.
Green, A. J.; Harvey, R. J.; Thompson, E. J.; Rossor, M. N. Increased tau in the cerebrospinal fluid of patients with frontotempral dementia and Alzheimer's disease. Neurosci. Lett., 1999, 259 (2), 133-135.
Molina, L.; Touchon, J.; Herpe, M.; Lefranc, D.; Duplan, L.; Cristol, J. P.; Sabatier, R.; Vermersch, P.; Pau, B.; Mourton-Gilles, C. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport, 1999, 10 (17), 3491-3495.
Otto, M.; Wiltfang, J.; Tumani, H.; Zerr, I.; Lantsch, M.; Kornhuber, J.; Weber, T.; Kretzschmar, H. A.; Poser, S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett., 1997, 225 (3), 210-212.
Mollenhauer, B.; Bibl, M.; Wiltfang, J.; Steinacker, P.; Ciesielczyk, B.; Neubert, K.; Trenkwalder, C.; Otto, M. Total tau protein, phosphorylated tau (181p) protein, beta amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin. Chem. Lab. Med., 2006, 44 (2), 192-195.
Schoonenboom, N. S.; Pijnenburg, Y. A.; Mulder, C.; Rosso, S. M.; Van Elk, E. J.; Van Kamp, G. J.; Van Swieten, J. C.; Scheltens, P. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset alzheimer disease. Neurology, 2004, 62 (9), 1580-1584.
Hu, Y. Y.; He, S. S.; Wang, X.; Duan, Q. H.; Grundke-Iqbal, I.; Iqbal, K.; Wang, J. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate- recycle enzyme-linked immunosorbent assay. Am. J. Pathol., 2002, 160 (4), 1269-1278.
Yamamori, H.; Khatoon, S.; Grundke-Iqbal, I.; Blennow, K.; Ewers, M.; Hampel, H.; Iqbal, K. Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. Neurosci. Lett., 2007, 418 (2), 186-189.
Selkoe, D. J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem., 1996, 271 (31), 18295-18298.
Peskind, E. R.; Li, G.; Shofer, J.; Quinn, J. F.; Kaye, J. A.; Clark, C. M.; Farlow, M. R.; DeCarli, C.; Raskind, M. A.; Schellenberg, G. D.; Lee, V. M.; Galasko, D. R. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch. Neurol., 2006, 63 (7), 936-939.
Jensen, M.; Schroder, J.; Blomberg, M.; Engvall, B.; Pantel, J.; Ida, N.; Basun, H.; Wahlund, L. O.; Werle, E.; Jauss, M.; Beyreuther, K.; Lannfelt, L.; Hartmann, T. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol., 1999, 45 (4), 504-511.
Tamaoka, A.; Sawamura, N.; Fukushima, T.; Shoji, S.; Matsubara, E.; Shoji, M.; Hirai, S.; Furiya, Y.; Endoh, R.; Mori, H. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J. Neurol. Sci., 1997, 148 (1), 41-45.
Mehta, P. D.; Pirttila, T.; Patrick, B. A.; Barshatzky, M.; Mehta, S. P. Amyloid beta protein 1-40 and 1-42 levels in matched cerebro- spinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett., 2001, 304 (1-2), 102-106.
Motter, R.; Vigo-Pelfrey, C.; Kholodenko, D.; Barbour, R.; Johnson-Wood, K.; Galasko, D.; Chang, L.; Miller, B.; Clark, C.; Green, R.; Reduction of beta-amyloid peptide42 in the cerebro-spinal fluid of patients with Alzheimer's disease. Ann. Neurol., 1995, 38 (4), 643-648.
Sunderland, T.; Linker, G.; Mirza, N.; Putnam, K. T.; Friedman, D. L.; Kimmel, L. H.; Bergeson, J.; Manetti, G. J.; Zimmermann, M.; Tang, B.; Bartko, J. J.; Cohen, R. M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA, 2003, 289 (16), 2094-2103.
Andreasen, N.; Minthon, L.; Vanmechelen, E.; Vanderstichele, H.; Davidsson, P.; Winblad, B.; Blennow, K. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett., 1999, 273 (1), 5-8.
Sjogren, M.; Vanderstichele, H.; Agren, H.; Zachrisson, O.; Edsbagge, M.; Wikkelso, C.; Skoog, I.; Wallin, A.; Wahlund, L. O.; Marcusson, J.; Nagga, K.; Andreasen, N.; Davidsson, P.; Vanmechelen, E.; Blennow, K. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem., 2001, 47 (10), 1776-1781.
Tschampa, H. J.; Schulz-Schaeffer, W.; Wiltfang, J.; Poser, S.; Otto, M.; Neumann, M.; Kretzschmar, H. A. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology, 2001, 56 (4), 576.
Nagga, K.; Gottfries, J.; Blennow, K.; Marcusson, J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord., 2002, 14 (4), 183-190.
Otto, M.; Esselmann, H.; Schulz-Shaefer, W.; Neumann, M.; Schroter, A.; Ratzka, P.; Cepek, L.; Zerr, I.; Steinacker, P.; Windl, O.; Kornhuber, J.; Kretzschmar, H. A.; Poser, S.; Wiltfang, J. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt Jakob disease. Neurology, 2000, 54 (5), 1099-1102.
Sjogren, M.; Minthon, L.; Davidsson, P.; Granerus, A.-K.; Clarberg, A.; Vanderstichele, H.; Vanmechelen, E.; Wallin, A.; Blen- now, K. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural Transm., 2000, 107 (5), 563-579.
Chromy, B. A.; Nowak, R. J.; Lambert, M. P.; Viola, K. L.; Chang, L.; Velasco, P. T.; Jones, B. W.; Fernandez, S. J.; Lacor, P. N.; Horowitz, P.; Finch, C. E.; Krafft, G. A.; Klein, W. L. Self- assembly of Abeta(1-42) into globular neurotoxins. Biochemistry, 2003, 42 (44), 12749-12760.
Gong, Y.; Chang, L.; Viola, K. L.; Lacor, P. N.; Lambert, M. P.; Finch, C. E.; Krafft, G. A.; Klein, W. L. Alzheimer's disease- affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA, 2003, 100 (18), 10417-10422.
Georganopoulou, D. G.; Chang, L.; Nam, J. M.; Thaxton, C. S.; Mufson, E. J.; Klein, W. L.; Mirkin, C. A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2005, 102 (7), 2273-2276.
Haes, A. J.; Chang, L.; Klein, W. L.; Van Duyne, R. P. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J. Am. Chem. Soc., 2005, 127 (7), 2264-2271.
Funke, S. A.; Birkmann, E.; Henke, F.; Gortz, P.; Lange- Asschenfeldt, C.; Riesner, D.; Willbold, D. Single particle detection of Abeta aggregates associated with Alzheimer's disease. Biochem. Biophys. Res. Commun, 2007, 364 (4), 902-907.
Akiyama, H.; Kondo, H.; Mori, H.; Kametani, F.; Nishimura, T.; Ikeda, K.; Kato, M.; McGeer, P. L. The amino-terminally truncated forms of amyloid beta-protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients. Neurosci. Lett., 1996, 219 (2), 115-118.
Wiltfang, J.; Esselmann, H.; Bibl, M.; Smirnov, A.; Otto, M.; Paul, S.; Schmidt, B.; Klafki, H. W.; Maler, M.; Dyrks, T.; Bienert, M.; Beyermann, M.; Ruther, E.; Kornhuber, J. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem., 2002, 81 (3), 481-496.
Sergeant, N.; Bombois, S.; Ghestem, A.; Drobecq, H.; Kostanjevecki, V.; Missiaen, C.; Wattez, A.; David, J. P.; Vanmechelen, E.; Sergheraert, C.; Delacourte, A. Truncated beta amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem., 2003, 85 (6), 1581-1591.
El, Mouedden M.; Vandermeeren, M.; Meert, T.; Mercken, M. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides. J. Neurosci. Methods, 2005, 145 (1-2), 97-105.
Riemenschneider, M.; Wagenpfeil, S.; Vanderstichele, H.; Otto, M.; Wiltfang, J.; Kretzschmar, H.; Vanmechelen, E.; Forstl, H.; Kurz, A. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol. Psychiatry, 2003, 8 (3), 343-347.
Irizarry, M. C. Biomarkers of Alzheimer disease in plasma. NeuroRx., 2004, 1 (2), 226 234.
Mehta, P. D. Amyloid beta protein as a marker or risk factor of Alzheimer's disease. Curr. Alzheimer Res., 2007, 4 (4), 359-363.
Kuo, Y. M.; Kokjohn, T. A.; Kalback, W.; Luehrs, D.; Galasko, D. R.; Chevallier, N.; Koo, E. H.; Emmerling, M. R.; Roher, A. E. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem. Biophys. Res. Commun., 2000, 268 (3), 750-756.
Lanz, T. A.; Schachter, J. B. Solid-phase extraction enhances detection of betaamyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies. J. Neurosci. Methods, 2008, 169 (1), 16-22.
Slemmon, J. R.; Painter, C. L.; Nadanaciva, S.; Catana, F.; Cook, A.; Motter, R.; Seubert, P. Distribution of Abeta peptide in whole blood. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 846 (1-2), 24-31.
Ray, S.; Britschgi, M.; Herbert, C.; Takeda-Uchimura, Y.; Boxer, A.; Blennow, K.; Friedman, L. F.; Galasko, D. R.; Jutel, M.; Karydas, A.; Kaye, J. A.; Leszek, J.; Miller, B. L.; Minthon, L.; Quinn, J. F.; Rabinovici, G. D.; Robinson, W. H.; Sabbagh, M. N.; So, Y. T.; Sparks, D. L.; Tabaton, M.; Tinklenberg, J.; Yesavage, J. A.; Tibshirani, R.; Wyss-Coray, T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med., 2007, 13 (11), 1359-1362.
Forno, L. S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol., 1996, 55 (3), 259-272.
Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci., 2001, 2 (7), 492-501.
Chartier-Harlin, M. C.; Kachergus, J.; Roumier, C.; Mouroux, V.; Douay, X.; Lincoln, S.; Levecque, C.; Larvor, L.; Andrieux, J.; Hulihan, M.; Waucquier, N.; Defebvre, L.; Amouyel, P.; Farrer, M.; Destee, A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 2004, 364 (9440), 1167-1169.
Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J. T.; Schols, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 1998, 18 (2), 106-108.
Morfis, L.; Cordato, D. J. Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation. J. Clin. Neurosci., 2006, 13 (9), 942-944.
Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E. S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W. G.; Lazzarini, A. M.; Duvoisin, R. C.; Di, Iorio G.; Golbe, L. I.; Nussbaum, R. L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276 (5321), 2045-2047.
Singleton, A. B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M. R.; Muenter, M.; Baptista, M.; Miller, D.; Blan- cato, J.; Hardy, J.; Gwinn-Hardy, K. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003, 302 (5646), 841.
Yamaguchi, K.; Cochran, E. J.; Murrell, J. R.; Polymeropoulos, M. H.; Shannon, K. M.; Crowther, R. A.; Goedert, M.; Ghetti, B. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha synuclein gene. Acta Neuropathol., 2005, 110 (3), 298-305.
Pals, P.; Lincoln, S.; Manning, J.; Heckman, M.; Skipper, L.; Hulihan, M.; Van den, Broeck M.; De, Pooter T.; Cras, P.; Crook, J.; Van, Broeckhoven C.; Farrer, M. J. alpha Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol., 2004, 56 (4), 591-595.
McKeith, I. G.; Dickson, D. W.; Lowe, J.; Emre, M.; O'Brien, J. T.; Feldman, H.; Cummings, J.; Duda, J. E.; Lippa, C.; Perry, E. K.; Aarsland, D.; Arai, H.; Ballard, C. G.; Boeve, B.; Burn, D. J.; Costa, D.; del, Ser T.; Dubois, B.; Galasko, D.; Gauthier, S.; Goetz, C. G.; Gomez-Tortosa, E.; Halliday, G.; Hansen, L. A.; Hardy, J.; Iwatsubo, T.; Kalaria, R. N.; Kaufer, D.; Kenny, R. A.; Korczyn, A.; Kosaka, K.; Lee, V. M.; Lees, A.; Litvan, I.; Londos, E.; Lopez, O. L.; Minoshima, S.; Mizuno, Y.; Molina, J. A.; Mukaetova- Ladinska, E. B.; Pasquier, F.; Perry, R. H.; Schulz, J. B.; Trojanowski, J. Q.; Yamada, M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 2005, 65 (12), 1863-1872.
El-Agnaf, O. M.; Salem, S. A.; Paleologou, K. E.; Curran, M. D.; Gibson, M. J.; Court JA; Schlossmacher, M. G.; Allsop, D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J., 2006, 20 (3), 419-425.
Tokuda, T.; Salem, S. A.; Allsop, D.; Mizuno, T.; Nakagawa, M.; Qureshi, M. M.; Locascio, J. J.; Schlossmacher, M. G.; El-Agnaf, O. M. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun., 2006, 349 (1), 162-166.
van Geel, W. J.; Abdo, W. F.; Melis, R.; Williams, S.; Bloem, B. R.; Verbeek, M. M. A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J. Neurosci. Methods, 2008, 168 (1), 182-185.
